|
1
|
van Hagen P, Hulshof MC, van Lanschot JJ,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ,
Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J
Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hongo M, Nagasaki Y and Shoji T:
Epidemiology of esophageal cancer: Orient to Occident. Effects of
chronology, geography and ethnicity. J Gastroenterol Hepatol.
24:729–735. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheung WY and Liu G: Genetic variations in
esophageal cancer risk and prognosis. Gastroenterol Clin North Am.
3875–91. (viii)2009.PubMed/NCBI
|
|
5
|
Wu C, Hu Z, He Z, Jia W, Wang F, Zhou Y,
Liu Z, Zhan Q, Liu Y, Yu D, et al: Genome-wide association study
identifies three new susceptibility loci for esophageal
squamous-cell carcinoma in Chinese populations. Nat Genet.
43:679–684. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu C, Li D, Jia W, Hu Z, Zhou Y, Yu D,
Tong T, Wang M, Lin D, Qiao Y, et al: Genome-wide association study
identifies common variants in SLC39A6 associated with length of
survival in esophageal squamous-cell carcinoma. Nat Genet.
45:632–638. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun
ZM, Zhang F, Zhao ZR, Li ZT, Liu ZY, et al: Genetic landscape of
esophageal squamous cell carcinoma. Nat Genet. 46:1097–1102. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gescher A, Steward WP and Brown K:
Resveratrol in the management of human cancer: How strong is the
clinical evidence? Ann N Y Acad Sci. 1290:12–20. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Frazzi R and Tigano M: The multiple
mechanisms of cell death triggered by resveratrol in lymphoma and
leukemia. Int J Mol Sci. 15:4977–4993. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park EJ and Pezzuto JM: The pharmacology
of resveratrol in animals and humans. Biochim Biophys Acta.
1852:1071–1113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Novelle MG, Wahl D, Diéguez C, Bernier M
and de Cabo R: Resveratrol supplementation: Where are we now and
where should we go? Ageing Res Rev. 21:1–15. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh CK, George J and Ahmad N:
Resveratrol-based combinatorial strategies for cancer management.
Ann N Y Acad Sci. 1290:113–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xue YQ, Di JM, Luo Y, Cheng KJ, Wei X and
Shi Z: Resveratrol oligomers for the prevention and treatment of
cancers. Oxid Med Cell Longev. 2014:7658322014.PubMed/NCBI
|
|
14
|
Yang X, Li X and Ren J: From French
Paradox to cancer treatment: Anti-cancer activities and mechanisms
of resveratrol. Anticancer Agents Med Chem. 14:806–825. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin Y, Yngve A, Lagergren J and Lu Y: A
dietary pattern rich in lignans, quercetin and resveratrol
decreases the risk of oesophageal cancer. Br J Nutr. 112:2002–2009.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kulkarni SS and Cantó C: The molecular
targets of resveratrol. Biochim Biophys Acta. 1852:1114–1123. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh CK, Ndiaye MA and Ahmad N:
Resveratrol and cancer: Challenges for clinical translation.
Biochim Biophys Acta. 1852:1178–1185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Britton RG, Kovoor C and Brown K: Direct
molecular targets of resveratrol: Identifying key interactions to
unlock complex mechanisms. Ann N Y Acad Sci. 1348:124–133. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tebbutt N, Pedersen MW and Johns TG:
Targeting the ERBB family in cancer: Couples therapy. Nat Rev
Cancer. 13:663–673. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hanawa M, Suzuki S, Dobashi Y, Yamane T,
Kono K, Enomoto N and Ooi A: EGFR protein overexpression and gene
amplification in squamous cell carcinomas of the esophagus. Int J
Cancer. 118:1173–1180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fichter CD, Gudernatsch V, Przypadlo CM,
Follo M, Schmidt G, Werner M and Lassmann S: ErbB targeting
inhibitors repress cell migration of esophageal squamous cell
carcinoma and adenocarcinoma cells by distinct signaling pathways.
J Mol Med (Berl). 92:1209–1223. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hoshino M, Fukui H, Ono Y, Sekikawa A,
Ichikawa K, Tomita S, Imai Y, Imura J, Hiraishi H and Fujimori T:
Nuclear expression of phosphorylated EGFR is associated with poor
prognosis of patients with esophageal squamous cell carcinoma.
Pathobiology. 74:15–21. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mitsudomi T and Yatabe Y: Epidermal growth
factor receptor in relation to tumor development: EGFR gene and
cancer. FEBS J. 277:301–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Olayioye MA, Neve RM, Lane HA and Hynes
NE: The ErbB signaling network: Receptor heterodimerization in
development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han W and Lo HW: Landscape of EGFR
signaling network in human cancers: Biology and therapeutic
response in relation to receptor subcellular locations. Cancer
Lett. 318:124–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kolch W and Pitt A: Functional proteomics
to dissect tyrosine kinase signalling pathways in cancer. Nat Rev
Cancer. 10:618–629. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J, Yu JM, Jing SW, Guo Y, Wu YJ, Li
N, Jiao WP, Wang L and Zhang YJ: Relationship between EGFR
over-expression and clinicopathologic characteristics in squamous
cell carcinoma of the esophagus: A meta-analysis. Asian Pac J
Cancer Prev. 15:5889–5893. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aichler M, Motschmann M, Jutting U, Luber
B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR and
Walch A: Epidermal growth factor receptor (EGFR) is an independent
adverse prognostic factor in esophageal adenocarcinoma patients
treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget.
5:6620–6632. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gan HK, Burgess AW, Clayton AH and Scott
AM: Targeting of a conformationally exposed, tumor-specific epitope
of EGFR as a strategy for cancer therapy. Cancer Res. 72:2924–2930.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lacouture ME: Mechanisms of cutaneous
toxicities to EGFR inhibitors. Nat Rev Cancer. 6:803–812. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schramm L: Going Green: The role of the
green tea component EGCG in chemoprevention. J Carcinog Mutagen.
4:10001422013.PubMed/NCBI
|
|
32
|
Russo GL, Russo M, Spagnuolo C, Tedesco I,
Bilotto S, Iannitti R and Palumbo R: Quercetin: A pleiotropic
kinase inhibitor against cancer. Cancer Treat Res. 159:185–205.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Levkowitz G, Waterman H, Ettenberg SA,
Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover
A, et al: Ubiquitin ligase activity and tyrosine phosphorylation
underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol
Cell. 4:1029–1040. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ettenberg SA, Keane MM, Nau MM, Frankel M,
Wang LM, Pierce JH and Lipkowitz S: cbl-b inhibits epidermal growth
factor receptor signaling. Oncogene. 18:1855–1866. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lin SY, Makino K, Xia W, Matin A, Wen Y,
Kwong KY, Bourguignon L and Hung MC: Nuclear localization of EGF
receptor and its potential new role as a transcription factor. Nat
Cell Biol. 3:802–808. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brand TM, Iida M, Luthar N, Starr MM,
Huppert EJ and Wheeler DL: Nuclear EGFR as a molecular target in
cancer. Radiother Oncol. 108:370–377. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li A, Zhang C, Gao S, Chen F, Yang C, Luo
R and Xiao H: TIP30 loss enhances cytoplasmic and nuclear EGFR
signaling and promotes lung adenocarcinogenesis in mice. Oncogene.
32:2273–2281, 2281e.1–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Umemura S, Takekoshi S, Suzuki Y, Saitoh
Y, Tokuda Y and Osamura RY: Estrogen receptor-negative and human
epidermal growth factor receptor 2-negative breast cancer tissue
have the highest Ki-67 labeling index and EGFR expression: Gene
amplification does not contribute to EGFR expression. Oncol Rep.
14:337–343. 2005.PubMed/NCBI
|
|
39
|
Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF
and Hung MC: Novel prognostic value of nuclear epidermal growth
factor receptor in breast cancer. Cancer Res. 65:338–348.
2005.PubMed/NCBI
|
|
40
|
Taguchi T: Nuclear translocation of
epidermal growth factor receptor and its relation to
clinicopathological factors in oral squamous cell carcinomas.
Kokubyo Gakkai Zasshi. 81:45–52. 2014.(In Japanese). PubMed/NCBI
|
|
41
|
Lo HW: Nuclear mode of the EGFR signaling
network: Biology, prognostic value, and therapeutic implications.
Discov Med. 10:44–51. 2010.PubMed/NCBI
|
|
42
|
Jaganathan S, Yue P, Paladino DC,
Bogdanovic J, Huo Q and Turkson J: A functional nuclear epidermal
growth factor receptor, SRC and Stat3 heteromeric complex in
pancreatic cancer cells. PLoS One. 6:e196052011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dittmann K, Mayer C and Rodemann HP:
Inhibition of radiation-induced EGFR nuclear import by C225
(Cetuximab) suppresses DNA-PK activity. Radiother Oncol.
76:157–161. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dittmann K, Mayer C, Wanner G, Kehlbach R
and Rodemann HP: The radioprotector O-phospho-tyrosine stimulates
DNA-repair via epidermal growth factor receptor- and DNA-dependent
kinase phosphorylation. Radiother Oncol. 84:328–334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liccardi G, Hartley JA and Hochhauser D:
Importance of EGFR/ERCC1 interaction following radiation-induced
DNA damage. Clin Cancer Res. 20:3496–3506. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dittmann K, Mayer C, Kehlbach R and
Rodemann HP: Radiation-induced caveolin-1 associated EGFR
internalization is linked with nuclear EGFR transport and
activation of DNA-PK. Mol Cancer. 7:692008. View Article : Google Scholar : PubMed/NCBI
|
